Wholesale Respiratory Devices for Costa Rica

SysMed includes a complete documentation set with every shipment, pre-formatted for Costa Rica's Dirección General de Aduanas: commercial invoices, certificates of origin, packing lists, and harmonized tariff codes for each device, alongside Ministerio de Salud registration references.

Applicable duties and taxes depend on each device's HS classification and country of manufacture; your customs broker confirms current treatment and calculates landed cost. Correctly prepared documentation keeps customs clearance predictable and avoids the delays that most often slow time-to-market.

Yes. Costa Rica keeps a procedure that recognizes the U.S. FDA's device registration and control system, and its current rule, Decreto 43902-S (RTCR 505:2022), lets the Ministerio de Salud (through its DRPIS division) accept the conformity results of recognized foreign registration systems with a reduced set of documents, instead of the full technical file of the standard route.

You still need to file formally through the Regístrelo portal: a certificate of free sale (for U.S. products, the FDA Certificate to Foreign Government), technical and medical specifications, Spanish-language labeling and a power of attorney for the local legal representative. With fewer documents to review, the process can move faster than a full evaluation, such as the review of up to 110 business days for Class III and IV devices in Argentina. Eligibility depends on each model's existing approvals, so SysMed confirms the applicable route model by model and provides CE marking and ISO 13485 documentation on request.

Strategically, yes. Costa Rica is a member of SICA (Central American Integration System), alongside Guatemala, Honduras, El Salvador, Nicaragua, Panama, Belize and the Dominican Republic.

SICA has no mutual recognition of device registrations (each country still requires its own registration), but having an established Costa Rica registration demonstrates regional regulatory familiarity and provides documentation that translates well across SICA member processes. For distributors evaluating a multi-country Central American strategy, Costa Rica is typically the best first market due to its well-defined Ministry of Health registration process and CAFTA-DR duty access.

Costa Rica has the highest asthma prevalence in Central America at 30%, nearly double the 17% regional average. COPD affects 9% of adults over 40, with an 88.7% underdiagnosis rate, meaning the vast majority of COPD cases aren't yet captured in the treatment system.

As diagnostic capacity expands under the CCSS's infrastructure investment plan, more patients will enter the treatment pipeline, driving institutional demand for CPAP, BiPAP, and oxygen therapy devices. For distributors, this creates a growing market with predictable trajectory: diagnosed prevalence is rising not because the disease is spreading, but because detection is improving. SysMed helps partners align inventory planning with this demand curve.

The CCSS (Caja Costarricense de Seguro Social) dominates Costa Rica's healthcare market. It provides universal coverage, operates 29 hospitals and over 1,000 EBAIS primary care centers, and manages more than 90% of public healthcare delivery. When the CCSS procures respiratory equipment, it buys at national scale through centralized tender processes.

These tenders follow structured timelines with specific documentation, pricing, and delivery requirements. The CCSS has committed USD 3B+ in infrastructure investment through 2030, which includes expansion of respiratory care capacity. For distributors, this means growing tender volumes and multi-year supply opportunities. SysMed helps partners prepare CCSS tender documentation, including product specifications, registration evidence, and volume pricing proposals.